ArriVent BioPharma (AVBP)

• Market cap: $976M
• 1 day: -3.19%
• 5 days: -5.17%
• 1 month: 14.26%
• 3 months: 24.75%
• 6 months: -7%
• Year to date: -13.94%
• 1 year: -10.73%
• 5 years: 18.2%
• 10 years: 18.2%
• Sector: Healthcare
• Industry: Biotechnology

About: ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

Employees: 52